Evidence map›Paper›PMID 35261407›Full record

Observational studyBulletin of the World Health Organization2022

An observational prospective cohort study of naloxone use at witnessed overdoses, Kazakhstan, Kyrgyzstan, Tajikistan, Ukraine.

Paul Dietze, Gilberto Gerra, Vladimir Poznyak, Giovanna Campello, Wataru Kashino, Dzhonbek Dzhonbekov, Tetiana Kiriazova, Danil Nikitin, Assel Terlikbayeva, Dzmitry Krupchanka and 1 more

Open access · diamondAbstract readObservational Study
In one paragraph

Observational study in Bulletin of the World Health Organization, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Paul DietzeBehaviours and Health Risks Program, Burnet Institute, 85 Commercial Rd, Melbourne, VIC, 3004, Australia.
Gilberto GerraMental Health Department, AUSL of Parma, Parma, Italy.
Vladimir PoznyakDepartment of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland.
Giovanna CampelloDrug Prevention and Health Branch, United Nations Office on Drugs and Crime, Vienna, Austria.
Wataru KashinoDrug Prevention and Health Branch, United Nations Office on Drugs and Crime, Vienna, Austria.
Dzhonbek DzhonbekovPublic Organization Prisma, Dushanbe, Tajikistan.
Tetiana KiriazovaUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Danil NikitinGlobal Research Institute Foundation, Bishkek, Kyrgyzstan.
Assel TerlikbayevaGlobal Health Research Center of Central Asia, Columbia School of Social Work, Almaty, Kazakhstan.
Dzmitry KrupchankaDepartment of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland.
Anja BusseDrug Prevention and Health Branch, United Nations Office on Drugs and Crime, Vienna, Austria.
United Nations Office on Drugs and Crime · ATWorld Health Organization · CHUkrainian Institute of Public Health Policy · UA

Funding

World Health Organization 001
6 · The paper itself

Abstract

Objective: To determine whether participation in the United Nations Office on Drugs and Crime (UNODC) and the World Health Organization's (WHO) Stop Overdose Safely (S-O-S) take-home naloxone training project in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine resulted in naloxone use at witnessed opioid overdoses. Methods: An observational prospective cohort study was performed by recruiting participants in the implementation of the S-O-S project, which was developed as part of the broader S-O-S initiative. Training included instruction on overdose responses and naloxone use. Study participants were followed for 6 months after completing training. The primary study outcome was participants' naloxone use at witnessed overdoses, reported at follow-up. Findings: Between 400 and 417 S-O-S project participants were recruited in each country. Overall, 84% (1388/1646) of participants were interviewed at 6-month follow-up. The percentage who reported witnessing an overdose between baseline and follow-up was 20% (71/356) in Tajikistan, 33% (113/349) in Kyrgyzstan, 37% (125/342) in Ukraine and 50% (170/341) in Kazakhstan. The percentage who reported using naloxone at their most recently witnessed overdose was 82% (103/125) in Ukraine, 89% (152/170) in Kazakhstan, 89% (101/113) in Kyrgyzstan and 100% (71/71) in Tajikistan. Conclusion: Implementation of the UNODC-WHO S-O-S training project in four low- to middle-income countries resulted in the reported use of take-home naloxone at around 90% of witnessed opioid overdoses. The percentage varied between countries but was generally higher than found in previous studies. Take-home naloxone is particularly important in countries where emergency medical responses to opioid overdoses may be limited.

Indexed as

Drug OverdoseOpioid-Related DisordersAnalgesics, OpioidHumansKazakhstanKyrgyzstanNaloxoneNarcotic AntagonistsProspective StudiesTajikistanUkraineAnalgesics, OpioidNaloxoneNarcotic Antagonists

Identifiers

PMID35261407
PMCPMC8886259
OpenAlexW4220892938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.